EMR stock forecast, quote, news & analysis

EMR's MACD Histogram just turned positive

The Moving Average Convergence Divergence (MACD) for EMR turned positive on September 22, 2026. Looking at past instances where EMR's MACD turned positive, the stock continued to rise in 31 of 45 cases over the following month. The odds of a continued upward trend are 69%.

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on September 22, 2026. You may want to consider a long position or call options on EMR as a result. In 56 of 93 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 60%.

EMR moved above its 50-day moving average on September 21, 2026 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for EMR crossed bullishly above the 50-day moving average on September 29, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 9 of 18 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 50%.

Following a +2.08% 3-day Advance, the price is estimated to grow further. Considering data from situations where EMR advanced for three days, in 212 of 342 cases, the price rose further within the following month. The odds of a continued upward trend are 62%.

EMR may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 5 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where EMR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 56%.

The Aroon Indicator for EMR entered a downward trend on September 24, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Profit vs. Risk Rating rating for this company is 28 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 75, placing this stock better than average.

The Tickeron PE Growth Rating for this company is 34 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 46 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.363) is normal, around the industry mean (5.342). P/E Ratio (34.877) is within average values for comparable stocks, (66.065). Projected Growth (PEG Ratio) (1.837) is also within normal values, averaging (1.879). Dividend Yield (0.014) settles around the average of (0.014) among similar stocks. P/S Ratio (4.409) is also within normal values, averaging (186.943).

The Tickeron Price Growth Rating for this company is 48 (best 1 - 100 worst), indicating steady price growth. EMR’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 61 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

EMR paid dividends on September 10, 2026